A Phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: a Gynecologic Oncology Group study

Landrum, Lisa

51
A Phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: a Gynecologic Oncology Group study

Tuesday, March 31, 2015: 8:05 AM

International Ballroom (Hilton Chicago)

L. M. Landrum¹, W. E. Brady², D. K. Armstrong³, K. N. Moore¹, P. A. DiSilvestro⁴, D. M. O'Malley⁵, M. E. Tenney⁶, P. G. Rose⁷ and P. M. Fracasso⁸
¹The University of Oklahoma, Oklahoma City, OK, ²Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, ³Johns Hopkins Kimmel Cancer Center, Baltimore, MD, ⁴Women & Infants Hospital, Brown University, Providence, RI, ⁵The Ohio State University, Columbus, OH, ⁶University of Chicago, Chicago, IL, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Virginia, Charlottesville, VA

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

51
A Phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: a Gynecologic Oncology Group study

51 A Phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: a Gynecologic Oncology Group study

51
A Phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: a Gynecologic Oncology Group study